🌍 Worldwide🩺 Medicine & Health📡 OpenAlex🕒 Updated November 2, 2026

Most-Cited GLP-1 and Obesity Drugs Papers This Year (2026)

As of November 2, 2026, “Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial” leads Most-Cited GLP-1 and Obesity Drugs Papers This Year with 22 citations. “Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions” is second and “Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures” third.

WhatsApp Telegram X Facebook ⓘ Methodology

🚫 No paid placement📡 Source: OpenAlex🕒 Updated November 2, 2026 ⓘ How we measure

Highlights: ⚔️ Neck and neck: Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

🩺2

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductionsKonstantinos Prokopidis · British Journal of Pharmacology · 2026-01-2322 citations

👑

🩺1

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialLouis J. Aronne et al. · Nature Medicine · 2026-05-1222 citations

🩺3

Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fracturesYi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2026-02-0620 citations

Full ranking

🩺

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial ↗ •🏆 Leader

Louis J. Aronne et al. · Nature Medicine · 2026-05-12

22 citationsCitations

🩺

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions ↗ •⚔️ Neck and neck

Konstantinos Prokopidis · British Journal of Pharmacology · 2026-01-23

22 citationsCitations

🩺

Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures ↗ •

Yi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2026-02-06

20 citationsCitations

🩺

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety ↗ •

Ariana M. Chao et al. · PLoS Medicine · 2026-01-14

16 citationsCitations

🩺

Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists ↗ •

Zicheng Wang et al. · JAMA Network Open · 2026-01-09

14 citationsCitations

🩺

Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons ↗ •

Chloe Lessard et al. · Obstetrics and Gynecology · 2026-01-08

13 citationsCitations

🩺

GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults ↗ •

Arthur Heng-Cheng Hsu et al. · Annals of Oncology · 2026-06-07

12 citationsCitations

🩺

Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management ↗ •

Jesse R. Burson et al. · Mental Health Clinician · 2026-02-01

9 citationsCitations

🩺

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety ↗ •

Nai Lee et al. · Diabetes/Metabolism Research and Reviews · 2026-03-26

8 citationsCitations

🩺

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies ↗ •

Abdulhameed Alhazmi et al. · Frontiers in Endocrinology · 2026-03-03

8 citationsCitations

How this ranking works

Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.

Methodology →

SourceOpenAlex

SignalCitations

Last updatedNov 2, 2026, 4:27 PM UTC

Top 10Citations of papers published this year